PPC
PCRX icon

Park Place Capital’s Pacira BioSciences PCRX Stock Holding History

Park Place Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,600
Closed -$24.1K – 860
2024
Q3 		$24.1K Hold
1,600
– – 0.01% 477
2024
Q2 		$45.8K Buy
+1,600
New +$45.5K 0.01% 368

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Park Place Capital's PCRX Position: Q4 2024 in Review

Park Place Capital sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 1,600 shares — an estimated $24.1K sold.

Park Place Capital first reported a position in PCRX in Q2 2024 and held it in 2 quarters. The position peaked at $45.8K in Q2 2024. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

  • Park Place Capital reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
  • Park Place Capital sold 1,600 Pacira BioSciences shares in Q4 2024, an estimated $24.1K.
  • Park Place Capital first reported a position in Pacira BioSciences in Q2 2024 and held it in 2 quarters.
  • Park Place Capital's Pacira BioSciences position peaked at $45.8K in Q2 2024.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Park Place Capital's 13F filing for Q4 2024, filed 17 Jan 2025.